Eslam M.Sarin S.K.Wong V.W.-S.Fan J.-G.Kawaguchi T.Ahn S.H.Zheng M.-H.Shiha G.Yilmaz Y.Gani R.Alam S.Dan Y.Y.JIA-HORNG KAOHamid S.Cua I.H.Chan W.-K.Payawal D.Tan S.-S.Tanwandee T.Adams L.A.Kumar M.Omata M.George J.2021-09-042021-09-0420201936-0533https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091819550&doi=10.1007%2fs12072-020-10094-2&partnerID=40&md5=96d69a80755db36795d6f327777bc654https://scholars.lib.ntu.edu.tw/handle/123456789/581725Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector. ? 2020, Asian Pacific Association for the Study of the Liver.[SDGs]SDG3alpha tocopherol; aramchol; cenicriviroc; elafibranor; high density lipoprotein; hydroxymethylglutaryl coenzyme A reductase inhibitor; liver protective agent; low density lipoprotein; metformin; obeticholic acid; pentoxifylline; pioglitazone; placebo; resmetirom; selonsertib; unclassified drug; abdominal ultrasonography; alcohol liver disease; aspartate aminotransferase to platelet ratio index; body weight gain; cancer screening; cholecystitis; cholelithiasis; chronic hepatitis B; chronic hepatitis C; Chronic Liver Disease Questionnaire; computer assisted tomography; diet; dyslipidemia; echography; Editorial; endoscopic sleeve gastroplasty; endoscopic surgery; epigenetics; esophagogastroduodenoscopy; esophagus varices; European Quality of Life 5 Dimensions 5 Level questionnaire; exercise; family history; fatty liver; fatty liver index; fibrosis 4 index; gastroesophageal varices; gastroplasty; genetic variation; hepatobiliary parameters; histopathology; human; hypertension; hyperuricemia; hypopituitarism; hypothyroidism; insulin resistance; intestine flora; lifestyle modification; lipoprotein blood level; liver biopsy; liver cell carcinoma; liver cirrhosis; liver resection; liver stiffness; liver transplantation; metabolic fatty liver; metabolic syndrome X; MRI proton density fat fraction; NAFLD Fibrosis Score; non insulin dependent diabetes mellitus; nuclear magnetic resonance imaging; obesity; ovary polycystic disease; patient-reported outcome; polycythemia; portal hypertension; practice guideline; prevalence; priority journal; Pro C3; proton nuclear magnetic resonance; pruritus; questionnaire; radiofrequency ablation; sarcopenia; sedentary lifestyle; Short Form 36; side effect; sleep disordered breathing; survival rate; transient elastography; treatment response; vibration controlled transient elastography; virus hepatitis; waist circumference; Asian continental ancestry group; fatty liver; liver; metabolism; practice guideline; Asian Continental Ancestry Group; Fatty Liver; Humans; Liver; Practice Guidelines as TopicEditorial10.1007/s12072-020-10094-2330060932-s2.0-85091819550